Form 8-K - Current report:
SEC Accession No. 0001193125-24-200272
Filing Date
2024-08-14
Accepted
2024-08-14 08:35:52
Documents
17
Period of Report
2024-08-14
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d838109d8k.htm   iXBRL 8-K 25597
2 EX-99.1 d838109dex991.htm EX-99.1 18132
6 GRAPHIC g838109g0814090701390.jpg GRAPHIC 33550
7 GRAPHIC g838109g0814090701645.jpg GRAPHIC 8708
8 GRAPHIC g838109img01.jpg GRAPHIC 6106
  Complete submission text file 0001193125-24-200272.txt   236043

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA vcnx-20240814.xsd EX-101.SCH 2841
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE vcnx-20240814_lab.xml EX-101.LAB 17235
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE vcnx-20240814_pre.xml EX-101.PRE 10806
20 EXTRACTED XBRL INSTANCE DOCUMENT d838109d8k_htm.xml XML 3533
Mailing Address 1895 MOUNT HOPE AVE ROCHESTER NY 14620
Business Address 1895 MOUNT HOPE AVE ROCHESTER NY 14620 585-271-2700
VACCINEX, INC. (Filer) CIK: 0001205922 (see all company filings)

EIN.: 161603202 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38624 | Film No.: 241204374
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)